Syndax’s axatilimab fails primary endpoint in pulmonary fibrosis trial

Investing.com•Mon, Oct 12, 2026, 08:04 PM•2 min read

Developing story — details emerging. Check the source link for the latest updates.

Source: [Investing.com](https://www.investing.com/news/company-news/syndaxs-axatilimab-fails-primary-endpoint-in-pulmonary-fibrosis-trial-93CH-4945124)

📰 Read Full Story

This is an aggregated headline summary. For the complete report, visit the original publisher.

Continue Reading at Investing.com ↗

#finance #syndax #axatilimab #fails #primary #endpoint #pulmonary #fibrosis #trial

More Headlines

FinanceInvesting.com• 20m ago

IMF cuts Latin America, Caribbean growth forecasts on energy shock, little AI boost

Developing story — details emerging. Check the source link for the latest updates.

FinanceInvesting.com• 20m ago

IMF says AI investment propping up global growth, but war and debt threaten outlook

Developing story — details emerging. Check the source link for the latest updates.

FinanceCNBC• 21m ago

SK Hynix, SoftBank shares plunge as tech stocks in Asia track Wall Street chip sell-off

Asian technology stocks tumbled Tuesday as a sell-off in U. S. semiconductor shares spilled into regional markets.

FinanceCNBC• 23m ago

Global economy to slow less than expected in 2026 as AI boom offsets war hit: IMF

The IMF raised its 2026 global growth forecast to 3. 1%, as AI investment helped offset the war’s energy shock.

FinanceInvesting.com• 26m ago

IMF expects gradual BOJ rate hike towards neutral setting

Developing story — details emerging. Check the source link for the latest updates.

FinanceInvesting.com• 26m ago

IMF sees higher energy prices and interest rates hitting UK growth

Developing story — details emerging. Check the source link for the latest updates.